8 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 4 Not applicable, 3 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 3, Unknown 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
Follow Pulmonary TB: new trials by email Literature Review of Pulmonary TB trials Research Report on Pulmonary TB
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease Extra 600mg of Rifampicin, Placebo - Pulmonary TB | Phase 3 | Not yet recruiting | Hamilton Health Sciences Corporation | 1000 | 2026-02-01 | 2025-08-12 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis | Phase 2 | Active not recruiting | Global Alliance for TB Drug Development | 309 | 2023-10-31 | 2026-06-24 |
| Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB Delamanid, Bedaquiline, RHEZ - Pulmonary TB | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 122 | 2022-04-12 | 2026-08-12 |
| Risk Factors and Biomarkers for Post-tuberculosis Lung Damage no intervention - Pulmonary TB | Recruiting | Peking University Third Hospital | 400 | 2022-01-01 | 2022-06-22 | |
| Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'. New management mode - Pulmonary TB, TB | Not applicable | Completed | Xi'an Jiaotong University | 450 | 2020-09-01 | 2022-06-29 |
| Promoting Overall Care and Management Related to Tuberculosis Infection Through Pharmaceutical Care and Text Messaging New management mode - Pulmonary TB | Not applicable | Unknown | Farman Ullah Khan | 600 | 2020-02-01 | 2020-12-02 |
| Xpert MTB/RIF Ultra Trial Xpert® MTB/RIF Ultra, Referral to the specialized TB clinics - Tuberculosis (TB), Pulmonary TB | Not applicable | Completed | Nestani Tukvadze | 778 | 2019-05-27 | 2025-08-22 |
| A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis 10 mg OPC-167832, 30 mg OPC-167832, 90 mg OPC-167832 - Pulmonary TB | Phase 1 / Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 122 | 2018-10-18 | 2023-11-18 |
| Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults ID93 + GLA-SE - Pulmonary TB | Phase 1 | Completed | Access to Advanced Health Institute (AAHI) | 48 | 2018-10-02 | 2023-06-01 |
| Performance Evaluation of TB Breath- and Cough-testing Platforms Rapid Biosensor Systems (RBS) TB Breathalyser, eNose AeonoseTM - Pulmonary TB, Diagnoses Diseases | Unknown | Find | 360 | 2017-05-29 | 2017-07-21 | |
| Comparison Between Two Strategies for the Diagnosis of TB sputum collection for acid fast bacilli - Pulmonary TB | Not applicable | Completed | Hopital Lariboisière | 34 | 2016-07-01 | 2017-04-28 |
| Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis ATT (Ethambutol, Pyrazinamide, INH, Rifampicin) - HIV Infection, Pulmonary TB | Phase 3 | Completed | Tuberculosis Research Centre, India | 331 | 2009-09-14 | 2019-04-10 |
| Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB. - Pulmonary TB | Completed | NYU Langone Health | 10 | 2006-01-01 | 2016-03-31 |
Tuberculosis, Pulmonary (13) · Tuberculosis (2) · COVID-19 (1) · Cigarette Smoking (1) · HIV Infections (1)
Actinomycetales Infections (13) · Bacterial Infections (13) · Bacterial Infections and Mycoses (13) · Gram-Positive Bacterial Infections (13) · Infections (13) · Lung Diseases (13) · Mycobacterium Infections (13) · Respiratory Tract Diseases (13) · Respiratory Tract Infections (13) · Tuberculosis (11) · RNA Virus Infections (2) · Virus Diseases (2) · Behavior (1) · Blood-Borne Infections (1) · Communicable Diseases (1)
Rifampin (4) · Isoniazid (3) · Ethambutol (2) · OPC-67683 (2) · Pharmaceutical Services (2) · Pyrazinamide (2) · bedaquiline (2) · Linezolid (1) · Protons (1) · TBAJ-876 (1) · pretomanid (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Access to Advanced Health Institute (AAHI) (1) · Farman Ullah Khan (1) · Find (1) · Global Alliance for TB Drug Development (1) · Hamilton Health Sciences Corporation (1) · Hopital Lariboisière (1) · NYU Langone Health (1) · Nestani Tukvadze (1) · Peking University Third Hospital (1) · Tuberculosis Research Centre, India (1) · Xi'an Jiaotong University (1)
South Africa (4) · Georgia (2) · Pakistan (2) · United States (2) · China (1) · France (1) · India (1) · Philippines (1) · Tanzania (1) · Uganda (1)
Yu Fang, Phd (2) · Amjad Khan, Phd (1) · Christopher Cousins, MBChB PhD (1) · Christopher Fox, PhD (1) · John Eikelboom, MBBS FRCPC (1) · Morounfolu Olugbosi, MD (1) · Narendran Gopalan, DNB (Chest) (1) · Prof. Andreas Diacon (1) · Prof. Rodney Dawson, MD (1) · Rany Condos, MD (1) · Sean Wasserman, MBChB PhD (1) · Soumya Swaminathan, MD (1)
PMID 29507938, PMID 30982671, PMID 34691079, PMID 36878897, PMID 38243296, PMID 38356837, PMID 39612928, PMID 39651910, PMID 41121745, PMID 41616265, PMID 42214407
272201400041C-0-0-1 (1)